You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advancing a Glioma Immunotherapy
SBC: IN CYTU, INC. Topic: 102DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics
SBC: Waldron International llc Topic: NIDADESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Clinical real-time resting state fMRI
SBC: NeurInsight, LLC Topic: 108DESCRIPTION provided by applicant Surgical resection of brain neoplasms aims at maximizing long term survival by gross total resection of tumor tissue while preserving the patientandapos s functional status Task based functional MRI fMRI is increasingly used as an adjunct to intra operative electrocorticography for mapping eloquent cortex but suffers a significant failure rate due to funct ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Personal Alcohol Management System: PALMS mobile platform for alcohol use disorders
SBC: VisionQuest Biomedical Inc Topic: 350DESCRIPTION provided by applicant Alcohol misuse is a significant public health problem not only in the US but around the world Just in the US alcohol misuse is estimated to be the second cause of preventable death at a cost of more than $ billion in a single year Further it is also estimated that it reduces the lives of those who died by years Screening and brief interventions have ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Structure activity relationship of small molecule inhibitors of human papillomavirus E protein will be tested
SBC: SUNNYLIFE PHARMA INC. Topic: NIAIDThe human papillomavirus HPV E protein is needed for viral replication Infection with high risk HPV types can progress to pre malignant lesions called dysplasias which over a period of years can eventuate in invasive and metastatic epithelial malignancies HPV E proteins bind to the ubiquitin ligase E AP and this complex targets p and other E binding proteins for proteasome mediated de ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza
SBC: EPIVAX, INC. Topic: NIAIDDESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Assay Platform for Measuring Endogenous Kinase Activity
SBC: Kinasense LLC Topic: 100DESCRIPTION provided by applicant Kinase inhibitors are an effective class of targeted therapy for oncology However heterogeneous patient response and acquired resistance continues to be a significant clinical and economic burden To overcome this problem drug developers are pursuing novel kinase inhibitors for existing kinase targets with new modes of inhibition and increased potency as wel ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health